Pemphigoid diseases are a group of autoimmune bullous dermatoses (AIBD) caused by autoantibodies binding to distinct structural proteins of the dermal-epidermal junction. 1 Within this group, bullous pemphigoid (BP) is the most frequent and characterized by autoantibodies targeting the hemidesmosomal proteins BP180 (type XVII collagen, COL17) and/or BP230. 1 The vast majority of BP patients show a generalized disease. Less frequently, skin lesions may be restricted to one or a few sites, for which the term localized BP (LBP) was coined. Presumptive triggers that have been described to precede the onset of LBP include radiotherapy, thermal and chemical irritation, ultraviolet (UV) and photodynamic therapy, and local injury, such as pressure and surgical treatments. [2][3][4][5][6][7][8] Despite these insights, scant data on the prevalence of LBP has been reported. To address this knowledge gap, we retrospectively evaluated the prevalence of LBP.